IN2014MN02127A - - Google Patents

Info

Publication number
IN2014MN02127A
IN2014MN02127A IN2127MUN2014A IN2014MN02127A IN 2014MN02127 A IN2014MN02127 A IN 2014MN02127A IN 2127MUN2014 A IN2127MUN2014 A IN 2127MUN2014A IN 2014MN02127 A IN2014MN02127 A IN 2014MN02127A
Authority
IN
India
Prior art keywords
compounds
calcium
crac
channel
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Nageswara Rao Irlapati
Gokul Keruji Deshmukh
Nilesh Raghunath Khedkar
Kiran Chandrashekhar Kulkarni
Zubair Abdul Wajid Shaikh
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN2127MUN2014 priority Critical patent/IN2014MN02127A/en
Publication of IN2014MN02127A publication Critical patent/IN2014MN02127A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2127MUN2014 2012-05-02 2013-05-01 IN2014MN02127A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2127MUN2014 IN2014MN02127A (es) 2012-05-02 2013-05-01

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN6KO2012 2012-05-02
IN1474KO2012 2012-12-28
IN2127MUN2014 IN2014MN02127A (es) 2012-05-02 2013-05-01
PCT/IB2013/053446 WO2013164773A1 (en) 2012-05-02 2013-05-01 Substituted pyrazole compounds as crac modulators

Publications (1)

Publication Number Publication Date
IN2014MN02127A true IN2014MN02127A (es) 2015-09-11

Family

ID=48428566

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2127MUN2014 IN2014MN02127A (es) 2012-05-02 2013-05-01

Country Status (7)

Country Link
US (2) US9409898B2 (es)
EP (1) EP2844656A1 (es)
AU (1) AU2013255441B2 (es)
CA (1) CA2871222A1 (es)
IN (1) IN2014MN02127A (es)
WO (1) WO2013164773A1 (es)
ZA (1) ZA201407668B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015197187A1 (en) * 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides v
WO2015197188A1 (en) * 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides as crac inhibitors
US20180161388A1 (en) 2015-05-18 2018-06-14 Beth Israel Deaconess Medical Center, Inc. Substance p, mast cell degranulation inhibitors, and peripheral neuropathy
KR20210062023A (ko) 2018-09-14 2021-05-28 리젠 파마슈티컬스 아게 Crac 억제제 및 코르티코스테로이드를 포함하는 조성물 및 그의 사용 방법
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
BR112021021028A2 (pt) 2019-06-06 2021-12-14 Basf Se Uso dos compostos de fórmula i, compostos da fórmula i, composição e método para combater fungos fitopatogênicos
CN110604735B (zh) * 2019-09-18 2022-10-25 华东师范大学 一种治疗肝纤维化、硬皮病的化合物及其应用
WO2021063735A1 (en) 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
AU3387999A (en) 1998-04-08 1999-10-25 Abbott Laboratories Pyrazole inhibitors of cytokine production
JP2002516909A (ja) * 1998-06-05 2002-06-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換１−（４−アミノフェニル）ピラゾール及び抗炎症剤としてのそれらの使用
DE602004030689D1 (de) 2003-07-23 2011-02-03 Synta Pharmaceuticals Corp Verbindungen gegen entzündungen und immun-relevante verwendungen
KR20070057965A (ko) 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
BRPI0606476A2 (pt) 2005-01-07 2009-06-30 Synta Pharmaceuticals Corp compostos para inflamação e usos imuno-relacionados e suas composições farmacêuticas
NZ556732A (en) 2005-01-25 2011-11-25 Synta Pharmaceuticals Corp Pyrazine compounds for inflammation and immune-related uses
JP5221147B2 (ja) 2005-01-25 2013-06-26 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫に関連する用途に用いる化合物
US8623871B2 (en) 2006-01-25 2014-01-07 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
JP2009524678A (ja) 2006-01-25 2009-07-02 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫関連用途のためのフェニル及びピリジル化合物
WO2007087441A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
PL1984338T3 (pl) 2006-01-31 2013-06-28 Synta Pharmaceuticals Corp Związki pirydylofenylowe do zastosowań związanych z zapaleniami i odpornością
TW200911800A (en) 2007-08-01 2009-03-16 Synta Pharmaceuticals Corp Pyridine compounds for inflammation and immune-related uses
MX2010002712A (es) 2007-09-10 2010-06-09 Calcimedica Inc Compuestos que modulan calcio intracelular.
US8389567B2 (en) 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2321303B1 (en) 2008-08-27 2019-11-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010039238A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
EP2477982A4 (en) 2009-09-16 2013-04-03 Calcimedica Inc COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
US8377970B2 (en) * 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
EP2606033A1 (de) 2010-08-20 2013-06-26 Grünenthal GmbH Substituierte cyclische carboxamid- und harnstoff-derivate als liganden des vanilloid-rezeptors
JP5387541B2 (ja) 2010-10-29 2014-01-15 住友電装株式会社 グロメット
EP3067347A1 (en) * 2010-10-30 2016-09-14 Lupin Limited Oxazoline and isoxazoline derivatives as crac modulators
JP2013545740A (ja) 2010-11-10 2013-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体
CA2834928C (en) 2011-05-03 2017-10-17 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2012325901A1 (en) 2011-10-19 2014-05-15 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium

Also Published As

Publication number Publication date
EP2844656A1 (en) 2015-03-11
CA2871222A1 (en) 2013-11-07
AU2013255441A1 (en) 2014-11-13
US20160304507A1 (en) 2016-10-20
US20150111925A1 (en) 2015-04-23
ZA201407668B (en) 2015-11-25
WO2013164773A1 (en) 2013-11-07
US9409898B2 (en) 2016-08-09
AU2013255441B2 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
IN2014MN02126A (es)
IN2014MN02127A (es)
CO6430427A2 (es) Derivados de benzofuranilo
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
PH12015500551A1 (en) Tricyclic quinoline and quinoline derivatives
GEP20166438B (en) Imidazopyrrolidinone compounds
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CR20110103A (es) Heteroarilos sustituidos
IN2014CN04907A (es)
MX367420B (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
MD20140109A2 (ro) Compuşi ai indolului şi indazolului care activează AMPK
IN2012DN00943A (es)
WO2012170931A3 (en) Compounds that modulate intracellular calcium
MX337711B (es) Compuestos que modulan el calcio intracelular.
MY162689A (en) Oxazoline and isoxazoline derivatives as crac modulators
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
EA026940B9 (ru) Замещенные хромановые соединения в качестве модуляторов чувствительного к кальцию рецептора
WO2012170951A3 (en) Compounds that modulate intracellular calcium
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
PH12014501979B1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
IN2015MN00421A (es)
MX357828B (es) Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
WO2013175347A3 (en) Compositions and methods for treatment of respiratory disorders